Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kobo Biotech's EBITDA for the
three
months ended in Mar. 2025 was ₹0.00 Mil. Kobo Biotech's Revenue for the
three
months ended in Mar. 2025 was ₹0.00 Mil. Therefore, Kobo Biotech's EBITDA margin for the quarter that ended in Mar. 2025 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Kobo Biotech EBITDA Margin % Related Terms
Kobo Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Kobo Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kobo Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kobo Biotech EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kobo Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Kobo Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kobo Biotech (BOM:531541) has a EBITDA Margin % of 0.00% as of Mar. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kobo Biotech and its competitors.
Is Kobo Biotech's EBITDA Margin % too high?
Kobo Biotech's current EBITDA Margin % is 0.00%. Overall, Kobo Biotech has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Kobo Biotech's EBITDA Margin % compare to ZTS?
Kobo Biotech's EBITDA Margin % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kobo Biotech and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kobo Biotech's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kobo Biotech stock overvalued right now?
Kobo Biotech (BOM:531541) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Kobo Biotech's overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kobo Biotech (BOM:531541), the current EBITDA Margin % is 0.00% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kobo Biotech Ltd is a pharmaceutical company. Its business comprises the manufacturing and sale of APIs (Active Pharmaceutical Ingredients) based on fermentation technology and Intermediates to pharmaceutical companies.
13GF Score
Get the complete analysis for BOM:531541
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531541 has been successfully added to your 
